INVIVYD, INC. Selling, General and Administrative Expense
INVIVYD, INC. (IVVD) reported Selling, General and Administrative Expense of $29.46 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-13
- INVIVYD, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $29.46M, a 77.63% increase year-over-year.
- INVIVYD, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $25.12M, a 49.94% increase year-over-year.
- INVIVYD, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $18.57M, a 28.85% increase year-over-year.
- INVIVYD, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $15.02M, a 15.92% increase year-over-year.
- INVIVYD, INC. selling, general and administrative expense for fiscal 2025 was $66.93M, a 5.59% increase from fiscal 2024.
- INVIVYD, INC. selling, general and administrative expense for fiscal 2024 was $63.39M, a 29.03% increase from fiscal 2023.
- INVIVYD, INC. selling, general and administrative expense for fiscal 2023 was $49.13M, a 4.42% increase from fiscal 2022.
- INVIVYD, INC. selling, general and administrative expense for fiscal 2022 was $47.04M.
| Period end | Selling, General and Administrative Expense 1 month | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 4 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 7 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $29.46M 10-Q · filed 2026-08-13 | $54.58M 10-Q · filed 2026-08-13 | $73.16M derived: sum of 3 quarters · filed 2026-08-13 | $88.17M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $25.12M 10-Q · filed 2026-05-14 | $43.69M derived: sum of 2 quarters · filed 2026-05-14 | $58.71M derived: sum of 3 quarters · filed 2026-05-14 | $75.30M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $18.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $33.59M derived: sum of 2 quarters · filed 2026-03-05 | $50.18M derived: sum of 3 quarters · filed 2026-08-13 | $66.93M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $15.02M 10-Q · filed 2025-11-06 | $31.61M derived: sum of 2 quarters · filed 2026-08-13 | $48.36M 10-Q · filed 2025-11-06 | $62.77M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $16.59M 10-Q · filed 2026-08-13 | $33.34M 10-Q · filed 2026-08-13 | $47.75M derived: sum of 3 quarters · filed 2026-08-13 | $60.71M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $16.75M 10-Q · filed 2026-05-14 | $31.17M derived: sum of 2 quarters · filed 2026-05-14 | $44.12M derived: sum of 3 quarters · filed 2026-05-14 | $65.21M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | $14.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $27.37M derived: sum of 2 quarters · filed 2026-03-05 | $48.46M derived: sum of 3 quarters · filed 2026-03-05 | $63.39M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $12.96M 10-Q · filed 2025-11-06 | $34.04M derived: sum of 2 quarters · filed 2025-11-06 | $48.97M 10-Q · filed 2025-11-06 | $64.06M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | $21.09M 10-Q · filed 2025-08-14 | $36.02M 10-Q · filed 2025-08-14 | $51.10M derived: sum of 3 quarters · filed 2025-08-14 | $63.99M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $14.93M 10-Q · filed 2025-05-15 | $30.02M derived: sum of 2 quarters · filed 2025-05-15 | $42.90M derived: sum of 3 quarters · filed 2025-05-15 | $53.01M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $15.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $27.97M derived: sum of 2 quarters · filed 2025-03-20 | $38.08M derived: sum of 3 quarters · filed 2025-03-20 | $49.13M 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $12.89M 10-Q · filed 2024-11-14 | $22.99M derived: sum of 2 quarters · filed 2024-11-14 | $34.04M 10-Q · filed 2024-11-14 | $44.56M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $10.11M 10-Q · filed 2024-08-14 | $21.15M 10-Q · filed 2024-08-14 | $31.67M derived: sum of 3 quarters · filed 2024-08-14 | $44.87M derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | $11.04M 10-Q · filed 2024-05-09 | $21.57M derived: sum of 2 quarters · filed 2024-05-09 | $34.77M derived: sum of 3 quarters · filed 2024-05-09 | $49.38M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $10.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $23.72M derived: sum of 2 quarters · filed 2024-03-28 | $38.34M derived: sum of 3 quarters · filed 2024-03-28 | $47.04M 10-K · filed 2024-03-28 | |||
| 2022-09-30 | $13.20M 10-Q · filed 2023-11-09 | $27.82M derived: sum of 2 quarters · filed 2023-11-09 | $36.52M 10-Q · filed 2023-11-09 | $51.19M derived: sum of 4 quarters · filed 2024-02-09 | |||
| 2022-06-30 | $14.62M 10-Q · filed 2023-08-10 | $23.32M 10-Q · filed 2023-08-10 | $37.99M derived: sum of 3 quarters · filed 2024-02-09 | $49.04M derived: sum of 4 quarters · filed 2024-02-09 | |||
| 2022-03-31 | $8.70M 10-Q · filed 2023-05-11 | $23.37M derived: sum of 2 quarters · filed 2024-02-09 | $34.42M derived: sum of 3 quarters · filed 2024-02-09 | $41.54M derived: sum of 4 quarters · filed 2024-02-09 | |||
| 2021-12-31 | $14.66M derived: 8-K 12 month − 10-Q 9 month · filed 2024-02-09 | $25.72M derived: sum of 2 quarters · filed 2024-02-09 | $32.84M derived: sum of 3 quarters · filed 2024-02-09 | $36.52M 8-K · filed 2024-02-09 | |||
| 2021-09-30 | $11.05M 10-Q · filed 2022-11-10 | $18.18M derived: sum of 2 quarters · filed 2022-11-10 | $21.85M 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | $7.12M 10-Q · filed 2022-08-15 | $10.70M 10-Q · filed 2022-08-15 | |||||
| 2021-03-31 | $3.68M 10-Q · filed 2022-05-13 | ||||||
| 2020-12-31 | $3.21M 10-K · filed 2022-03-31 | ||||||
| 2020-09-30 | $842.00K 10-Q · filed 2021-11-15 | $892.00K 10-Q · filed 2021-11-15 | |||||
| 2020-06-30 | $50.00K 10-Q · filed 2021-09-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |